These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
584 related articles for article (PubMed ID: 15717629)
1. Significance of proto-oncogene Bcl-X(S/L) expression in Wilms tumor. Basta-Jovanović G; Radonjic V; Stolic I; Nenadovic M; Brasanac D; Jovanovic D; Radojevic-Skodric S Ren Fail; 2005; 27(1):13-8. PubMed ID: 15717629 [TBL] [Abstract][Full Text] [Related]
2. The prognostic significance of apoptosis-associated proteins BCL-2, BAX and BCL-X in clinical nephroblastoma. Ghanem MA; Van der Kwast TH; Den Hollander JC; Sudaryo MK; Van den Heuvel MM; Noordzij MA; Nijman RJ; Soliman EH; van Steenbrugge GJ Br J Cancer; 2001 Nov; 85(10):1557-63. PubMed ID: 11720445 [TBL] [Abstract][Full Text] [Related]
3. Immunohistochemical analysis of gamma catenin in Wilms' tumors. Basta-Jovanovic G; Gvozdenovic E; Dimitrijevic I; Brasanac D; Jovanovic M; Kalezic N; Baralic I; Radojevic-Skodric S; Arsic D Fetal Pediatr Pathol; 2008; 27(2):63-70. PubMed ID: 18568994 [TBL] [Abstract][Full Text] [Related]
4. Results of the SIOP 93-01/GPOH trial and study for the treatment of patients with unilateral nonmetastatic Wilms Tumor. Reinhard H; Semler O; Bürger D; Bode U; Flentje M; Göbel U; Gutjahr P; Leuschner I; Maass E; Niggli F; Scheel-Walter HG; Stöckle M; Thüroff JW; Tröger J; Weirich A; von Schweinitz D; Zoubek A; Graf N Klin Padiatr; 2004; 216(3):132-40. PubMed ID: 15175957 [TBL] [Abstract][Full Text] [Related]
5. Differential expression of the drug resistance markers DNA topoisomerase II alpha and glutathione S-transferase-pi in the histological compartments of Wilms' tumors. Granzen B; Efferth T; Keller U; Beniers AJ; Mertens R; Jakse G; Füzesi L Anticancer Res; 2001; 21(1B):771-6. PubMed ID: 11299842 [TBL] [Abstract][Full Text] [Related]
6. Expression of Bcl-X(L), an antiapoptotic member of the Bcl-2 family, in esophageal squamous cell carcinoma. Torzewski M; Sarbia M; Heep H; Dutkowski P; Willers R; Gabbert HE Clin Cancer Res; 1998 Mar; 4(3):577-83. PubMed ID: 9533524 [TBL] [Abstract][Full Text] [Related]
8. Anaplasia and drug selection-independent overexpression of the multidrug resistance gene, MDR1, in Wilms' tumor. Re GG; Willingham MC; el Bahtimi R; Brownlee NA; Hazen-Martin DJ; Garvin AJ Mod Pathol; 1997 Feb; 10(2):129-36. PubMed ID: 9127318 [TBL] [Abstract][Full Text] [Related]
9. High bad and bcl-xL gene expression and combined bad, bcl-xL, bax and bcl-2 mRNA levels: molecular predictors for survival of stage 2 soft tissue sarcoma patients. Köhler T; Würl P; Meye A; Lautenschläger C; Bartel F; Borchert S; Bache M; Schmidt H; Holzhausen HJ; Taubert H Anticancer Res; 2002; 22(3):1553-9. PubMed ID: 12168836 [TBL] [Abstract][Full Text] [Related]
11. Effects of chemotherapy on the cytogenetic constitution of Wilms' tumor. Schlomm T; Gunawan B; Schulten HJ; Sander B; Thangavelu K; Graf N; Leuschner I; Ringert RH; Füzesi L Clin Cancer Res; 2005 Jun; 11(12):4382-7. PubMed ID: 15958621 [TBL] [Abstract][Full Text] [Related]
12. Myogenesis in Wilms' tumors is associated with mutations of the WT1 gene and activation of Bcl-2 and the Wnt signaling pathway. Fukuzawa R; Heathcott RW; Sano M; Morison IM; Yun K; Reeve AE Pediatr Dev Pathol; 2004; 7(2):125-37. PubMed ID: 14994125 [TBL] [Abstract][Full Text] [Related]
13. Bilateral Wilms' tumor with anaplasia: lessons from the National Wilms' Tumor Study. Hamilton TE; Green DM; Perlman EJ; Argani P; Grundy P; Ritchey ML; Shamberger RC J Pediatr Surg; 2006 Oct; 41(10):1641-4. PubMed ID: 17011261 [TBL] [Abstract][Full Text] [Related]
14. Immunohistochemical detection of p53 in Wilms' tumors correlates with unfavorable outcome. Lahoti C; Thorner P; Malkin D; Yeger H Am J Pathol; 1996 May; 148(5):1577-89. PubMed ID: 8623926 [TBL] [Abstract][Full Text] [Related]
15. Prognostic significance of Bcl-2 in Wilms' tumor and oncogenic potential of Bcl-X(L) in rare tumor cases. Re GG; Hazen-Martin DJ; El Bahtimi R; Brownlee NA; Willingham MC; Garvin AJ Int J Cancer; 1999 Apr; 84(2):192-200. PubMed ID: 10096254 [TBL] [Abstract][Full Text] [Related]
16. p53 expression in Wilms' tumor: a possible role as prognostic factor. Beniers AJ; Efferth T; Füzesi L; Granzen B; Mertens R; Jakse G Int J Oncol; 2001 Jan; 18(1):133-9. PubMed ID: 11115550 [TBL] [Abstract][Full Text] [Related]
17. Expression and prognostic value of Wilms' tumor 1 and early growth response 1 proteins in nephroblastoma. Ghanem MA; Van der Kwast TH; Den Hollander JC; Sudaryo MK; Oomen MH; Noordzij MA; Van den Heuvel MM; Nassef SM; Nijman RM; Van Steenbrugge GJ Clin Cancer Res; 2000 Nov; 6(11):4265-71. PubMed ID: 11106242 [TBL] [Abstract][Full Text] [Related]
18. Prognostic value of p53 expression in Wilms' tumor in children. Skotnicka-Klonowicz G; Kobos J; Łoś E; Trejster E; Szymik-Kontorowicz S; Daszkiewicz P Med Sci Monit; 2001; 7(6):1224-9. PubMed ID: 11687734 [TBL] [Abstract][Full Text] [Related]
19. The prognostic relevance of preoperative transcatheter arterial chemoembolization (TACE) and PCNA/VEGF expression in patients with Wilms' tumour. Liu WG; Gu WZ; Zhou YB; Tang HF; Li MJ; Ma WX Eur J Clin Invest; 2008 Dec; 38(12):931-8. PubMed ID: 19021718 [TBL] [Abstract][Full Text] [Related]
20. [Treatment of advanced Wilms' tumor]. Li MJ; Huang Y; Tang DX; Zhou YB; Tang HF; Liang JF Zhonghua Zhong Liu Za Zhi; 2006 Oct; 28(10):791-5. PubMed ID: 17366799 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]